This study was designed to determine whether blood pressure reduction, per se, causes adverse effects on cognitive and behavioral function in elderly hypertensive patients. Men with mild-to-moderate diastolic hypertension who had passed their 60th birthday were entered into the trial. After a placebo washout period, they were assigned in a randomized, double-blind manner to one of two groups receiving hydrochlorothiazide (either 25 mg once or twice daily or 50 mg once or twice daily). Responders entered a 1-year maintenance period. Nonresponders were randomly assigned to double-blind treatment with hydralazine, methyldopa, metoprolol, or reserpine added to the diuretic therapy. During the placebo and treatment periods, patients underwent a battery of psychometric tests designed to assess cognitive function, motor skills, memory, and affect. A separate questionnaire assessed the patient's ability to perform activities of daily living. A subset of patients blindly being treated with placebo received the same battery of tests as a control for practice effect. The results showed that there was similar improvement on the psychometric tests between those patients whose blood pressure was successfully reduced and the placebo-treated control group. Therefore, the practice effect did not obscure a true deterioration in function. There were no substantive differences between the lower and higher doses of diuretic or among the four drugs added to the diuretic, although there were qualitative differences in side effects. We conclude that blood pressure reduction, per se, does not adversely affect cognitive and behavioral function in elderly hypertensive patients and that antihypertensive treatment is safe and effective in these patients. (Hypertension 1990;15:361-369) E levated blood pressure in elderly patients can be safely and effectively reduced by using either hydrochlorothiazide (HCTZ) alone or, if necessary, by the addition of hydralazine, methyldopa, metoprolol, or reserpine to HCTZ.
To our knowledge, no detailed quality of life studies have been performed on elderly patients whose blood pressure has been successfully reduced 362 Hypertension Vol 15, No 4, April 1990 one of four drugs that were taken in addition to the prior dose of HCTZ. These drugs were hydralazine (50-200 mg daily), methyldopa (500-2,000 mg daily), metoprolol (100-400 mg daily), and reserpine (0.05-0.25 mg daily). All drugs were administered in a double-blind format. Patients who achieved goal blood pressure with the combination of HCTZ and one of the above drugs also were entered into a 6-month maintenance phase.
Behavioral Assessment
The behavioral assessment was conducted at the first or second prerandomization (placebo) visit, at the last HCTZ titration visit, at the end of titration of the drugs added to HCTZ, and at the end of the maintenance period. This assessment consisted of a battery of neuropsychological tests, an Activities of Daily Living (ADL) questionnaire and the Zung Depression Scale. 6 The ADL questionnaire was a modified version of the questionnaire used as part of the Comprehensive Assessment and Referral Evaluation (CARE). 7 The neuropsychological tests were chosen to obtain a brief assessment of general intelligence, complex cognitive abilities, memory, language, visualspatial abilities, and motor skills. General intelligence was only assessed at the initial evaluation, but the other areas were assessed at all testing occasions. The measure of general intelligence used was the Intellectual Processes scale of the Luria-Nebraska Neuropsychological Battery, 8 because of its high correlation with the full Wechsler Adult Intelligence Scale. Complex cognitive abilities were assessed with the Trail Making Test, the Smith Symbol Digit Modalities test, and time estimation. Although not precisely a complex cognitive task, time estimation was included because of reports in the literature stating that individuals with hypertension may develop an altered time sense. 9 Memory was evaluated with a three-word, short-term memory task with rehearsal prevention, portions of the Benton Visual Retention test, and a subset of the Wechsler Memory Scale (WMS), including the Logical Memory, Digit Span, and Paired Associate Learning portions of this scale with immediate and delayed recall of the Logical Memory subtest. Language was assessed with a controlled word production (verbal fluency) test and the Token test. The Hooper Visual Organization test was used to assess visual-spatial skills, and the Halstead Finger Tapping test was used to evaluate motor skill. These tests are extensively described elsewhere. 810 Specific details of each test can be obtained by writing to the first author.
Because of time constraints, and to minimize the influence of practice effects, some of these tests were abbreviated such that the patient was administered different items at each session. For example, in testing logical memory, the patient was asked to recall a different but equally lengthy story at each session. Different words, equated for frequency of usage in the language, were used at each session for the three-word, short-term memory test. Equating of these alternate test forms for level of difficulty was based on normative information available in the various test manuals.
To gain assurance that the tests selected would be sensitive to the subtle changes that might be associated with mild-to-moderate hypertension or to medication effects, most of the tests were chosen because they had been previously used in studies in which their sensitivity to presence or absence of hypertension or sensitivity to antihypertensive medication was demonstrated. 11 For example, time estimation was studied because untreated hypertensive subjects were found to have poorer time judgment than normotensive subjects but improved with treatment. 9 The ADL questionnaire covered the broad areas of personal hygiene and other instrumental self-care activities, household and social activities, and ambulation. Patients were also asked specifically about drowsiness and sexual problems. Each item was scored as difficulty present, difficulty absent, or no information.
The Zung Depression scale was given in the standard manner, with the patient responding to the 20 items. The total score was used as the dependent measure. The Zung scale was chosen because of the extensive work done with it in the area of geriatric depression 12 and because of reports attesting to its sensitivity to mild changes in affect in elderly patients. 13 These procedures were also administered by clinic staff members at the time of the neuropsychological assessment.
Testing was conducted by designated staff members of the hypertension research clinics at the seven participating Department of Veterans Affairs medical centers. These individuals were trained in test administration by the senior author and staff before initiation of data collection, and periodic meetings were held to resolve difficulties. All testers were blinded. The test protocols were forwarded to a central laboratory where they were evaluated and scored by the senior author and a trained neuropsychology technician, who were also blinded to study medications that the patient was taking. This central laboratory also prepared test form kits such that for each patient an alternate form of the tests would be presented at each testing session. The completed test protocols were forwarded to the project biostatistician for data analysis.
Practice Effects Substudy
Because of the possibility that favorable changes in neuropsychological test scores could be produced largely by familiarity with the test materials, a practice effect substudy was conducted. Fifty-five patients who were comparable to the main study patients demographically and with regard to initial blood pressure values were administered the neuropsychological test battery on two occasions, spaced 2-3 months apart. These patients were placed on blinded placebo over that period of time. n, the range of number of tests for the items in each column.
•Significantly different from baseline to end of titration or maintenance, p<0.05. tSignificantly different between low and high dose hydrochlorothiazide (HCTZ)/J<0.05.
Methodology for Data Management and Analysis
Data management and analyses were directed toward evaluation of whether the various treatment regimens were associated with detrimental changes in neuropsychological function, functional capacities, and affect. Therefore, the design was of the longitudinal, repeated-measures type in which periodic assessments are made under varying conditions. The neuropsychological test and Zung scale results were subjected to across-drug and within-drug comparisons, using analysis of variance and t tests for paired data. The across-drug comparisons were to determine whether there were significant differences in magnitude of change in score between the drugs. The within-drug comparisons evaluated whether there were significant changes in score between testing occasions for each individual drug. Although the neuropsychological tests and Zung scale generated metric data and could be analyzed with conventional general linear models methods, the ADL questionnaire produced frequency data that were analyzed with the Breslow-Day 14 and McNemar tests, both of which are \ 2 variants. Ap value of <0.05 for each test was considered statistically significant.
Because of the large number of neuropsychological tests administered, the baseline data were factor analyzed by using an iterated principal factor method. 15 A three-factor solution was chosen and factor scores were computed for the factors at each test point by multiplying each baseline factor coefficient by the specific test result obtained at the particular study phase and summing all resultant products. The first factor received high loadings from tests of complex cognitive abilities, the second from tests of memory, and the third from tests of motor speed. Both the factor scores and the results from the individual tests are presented. The analyses incorporated all available data. In general, all randomized patients were included in the titration phase analyses, except those who were lost to follow-up, those who refused to repeat the psychometric tests, and those with an emergency medical complication that prevented them from completing a terminating visit. Less serious side effects and blood pressure above safety limits were not exclusions from the analysis. The end of maintenance analyses are restricted to those patients entering the maintenance period and do not include all randomized patients.
Results

Comparison of Low and High Dose Hydrochlorothiazide
The randomized groups were well balanced for educational level and the neuropsychological tests at prerandomization baseline. Each group averaged 10.6 years of education. Only three of 18 tests had statistically significantly different means between the two randomized groups, and these differences were not large ( Table 1) . One of the three factor scores was significantly different between the two groups at baseline, but the difference was small.
All of the tests of complex ability and language showed statistically significant improvement from baseline to the end of titration and from baseline to the end of maintenance. This held true for both HCTZ groups. By contrast, there were only sporadic improvements observed for the memory tests and for the visual and motor tests ( Table 1) . None of the 18 individual tests showed a deterioration in their mean values from baseline to the end of titration or from baseline to the end of maintenance for either HCTZ group, demonstrating that antihypertensive treatment with HCTZ did not cause a decline of function. The factor scores for complex cognitive ability improved significantly for both HCTZ groups at each time period. In contrast, the factor scores for memory and motor speed improved significantly only for the high dose HCTZ group and only from baseline to the end of the maintenance period ( Table 1) .
The changes in all of the individual tests and the three factor scores from baseline to the end of titration and from baseline to the end of maintenance were compared between the low and high dose HCTZ groups. None of these comparisons was statistically significant ( Table 1 ), demonstrating that the two dose levels of HCTZ had no differential effects on neuropsychological function.
The randomized groups were also well balanced for the ADL questions at prerandomization baseline. Only one of the six questions was statistically significantly different between the two HCTZ groups at baseline ( Table 2) . None of the ADL factors deteriorated over time in either the low dose or high dose HCTZ groups. Some ADL factors showed improvement over time, including personal hygiene in the low dose HCTZ group, ambulation in both HCTZ groups, and alertness in the high dose HCTZ group. When changes in problems with ADL factors were compared between the low and high dose HCTZ groups, no statistically significant differences were found.
At prerandomization, the mean Zung score was 43.7±9.1 (SD) for the low dose HCTZ group and 43.7±9.2 for the high dose HCTZ group. At the end of titration, the corresponding mean values were 43.8±8.9 and 43.8±9.1. At the end of maintenance, the corresponding mean values were 42.0±9.0 and 42.1±9.3. None of the means between or within dose groups was significantly different.
At baseline 22.8% of the patients in the low dose HCTZ group and 22.0% of the patients in the high dose HCTZ group had clinical depression (Zung score greater than 50). At the end of titration, the corresponding percentages were 24.1% and 23.2%. At the end of maintenance, the corresponding percentages were 19.3% and 16.9%. None of the percentages between or within dose groups was significantly different. 
Ii a?
tion of test results obtained at the time of randomization to one of the four additional drugs showed the groups to be comparable. None of the tests had statistically significantly different means among the four groups (Table 3) . Data obtained at the end of HCTZ titration were considered baseline for the group requiring an additional drug. With regard to changes within each group from baseline to end of titration, the hydralazine group significantly improved on three tests: time estimation, controlled word production, and the Hooper; the methyldopa group improved on four tests: Trails B, Smith symbol digit, time estimation, and the Hooper; the metoprolol group improved on four tests: Trails B, Smith symbol digit, delayed logical memory, and the Hooper; the reserpine group improved on the Hooper. Methyldopa patients had significantly higher scores for the complex cognition factor, and the metoprolol group improved on the memory factor (Table 3) .
From baseline to end of maintenance, hydralazine patients improved on nine tests, methyldopa on eight, metoprolol on five, and reserpine on one ( Table 3 ). The tests showing improvement for hydralazine were time estimation, logical memory, easy and hard paired associates, short term memory with 30 second delay, controlled word production, the token test, the Hooper, and finger tapping with the dominant hand. This group also improved on the memory factor. The methyldopa patients had significantly improved scores for Trails B, Smith symbol digit, time estimation, logical memory, delayed logical memory, digits forward, controlled word production, the token test, and the complex cognition factor. Metoprolol patients improved on Trails B, time estimation, logical memory, delayed logical memory, the Hooper, and the memory factor. Reserpine patients improved on the Hooper. None of the groups showed significantly worse performance on any of the tests or factors either at the end of titration or the end of maintenance when compared with baseline.
The changes in test results and factor scores from baseline to the end of titration and from baseline to the end of maintenance were compared among the four treatment groups (Table 3) . None of the changes during titration was significantly different across the treatment groups. Comparing changes from baseline to end of maintenance, the four groups were significantly different on the hard paired associates test, finger tapping with the dominant hand, and the complex cognition factor. The improvement in the hydralazine group on the paired associates hard test was significantly different from the decline in the reserpine group. Improved finger tapping for the hydralazine group was significant when compared with the deterioration in the methyldopa and metoprolol groups. The complex cognition factor improved significantly in the methyldopa group when compared with no change in the metoprolol group.
Responses to the ADL questions were not significantly different across treatment groups at baseline, end of titration, or end of maintenance (Table 4) . Among hydralazine patients, more problems with sexual activities and fewer problems with alertness were seen at end of maintenance when compared with baseline. Methyldopa patients had a decrease in personal hygiene problems and an increase in ambulation problems during titration. However, during maintenance the rate of ambulation problems fell to baseline levels. Metoprolol patients had fewer social activity problems during titration but an increased prevalence of sexual activity problems in maintenance. Problems with ambulation increased for reserpine patients during titration and maintenance (Table 4) .
At baseline, the mean Zung scores for hydralazine, methyldopa, metoprolol, and reserpine were 43.0±9.0, 44.5±9.3, 46.2±7.9, and 45.6±9.8, respectively. None of these scores changed significantly within each group and comparisons across groups showed no differences. The corresponding mean scores at the end of maintenance were 40.6±8.5, 42.6±8.3, 44.7±10.5, and 44.4±8. 6 .
Rates of clinical depression in each group before randomization were 19.4% for hydralazine, 26.8% for methyldopa, 29.2% for metoprolol, and 35.4% for reserpine. The rate for the metoprolol group increased from baseline to end of maintenance. The rates at the end of maintenance were 19.2%, 21.8%, 37.2%, and 28.2%, respectively. However, none of the rate changes were significantly different within or across treatment groups.
Practice Effect Substudy
The percentage improvement in test scores from the first to second administration of the neuropsychological test battery was compared between the main study group of 690 men and the practice effects substudy group of 55 men. These results are presented in Table 5 . Percentage improvements were comparable for 15 of the 18 tests. More improvement in time estimation was observed for the HCTZtreated patients compared with the placebo-treated patients. The placebo-treated patients had greater improvement on two tests-delayed logical memory and digits backward.
Discussion
This investigation, which was described in part I, was designed to evaluate whether antihypertensive therapy in mildly to moderately hypertensive elderly men interfered with cognitive and behavioral functions. These were classified into three types. The first of them is the broad category of neuropsychological function. It has been reported that antihypertensive medications may impair memory, learning ability, psychomotor speed, and related cognitive processes. The second type relates to functional self-care skills or capacity for various ADL. The third commonly reported consequence is that these medications may cause depression. The major hypothesis was that if blood pressure reduction in general or any of the treatment regimens proved to be detrimental, it would be reflected in the results of test procedures that assess these aspects of behavior. That is, there would be increased neuropsychological deficit or depression, or decreased capacity for self-care.
In general, neither blood pressure reduction per se, nor any of the antihypertensive medications chosen for this study appeared to produce these previously implicated adverse behavioral effects. When HCTZ was given as monotherapy, there was no evidence of deterioration in any of the parameters measured. Furthermore, no differences were seen between the low (up to 50 mg/day) and high (up to 100 mg/day) dose regimens. Among those patients who did not achieve an adequate blood pressure response to HCTZ alone, one of four medications was added to the diuretic therapy: hydralazine, methyldopa, metoprolol, or reserpine. For the most part, combined therapy was not associated with decrement in neuropsychological function in any of the areas evaluated, capacity to perform functional activities of 368 Hypertension Vol 15, No 4, April 1990 daily living, or acquisition of clinically significant depression.
However, the combination therapy phase produced some, albeit minor, within-group adverse treatment effects or differential treatment changes. For the neuropsychological battery, although no deterioration was seen for any component within any of the four treatment groups, differential effects across treatments appeared for three tests. Hydralazine patients performed better on the hard paired associates test compared with reserpine patients. Methyldopa and metoprolol patients did worse than hydralazine patients on the finger tapping test using the dominant hand. Methyldopa patients scored higher on the complex cognition factor compared with metoprolol patients. Finally, although there was a general improvement in function on combination therapy, reserpine patients improved on only one test compared with five for the metoprolol group, eight for the methyldopa group, and nine for the hydralazine group. Thus, if these medications do indeed produce adverse changes in function, they appear to be subtle and of minor clinical importance.
With regard to ADL and affective state, metoprolol and, to a lesser extent, hydralazine, were associated with increased complaints concerning sexual function, while metoprolol was slightly more implicated in development of depression measured as the percentage of patients with scores above 50. However, mean Zung scores for the metoprolol patients did not change, thus attenuating the clinical significance of this finding to some extent.
It is well known that neuropsychological function is difficult to measure, and the inability to detect changes may reflect the selection of instruments that are insensitive. Most of the tests chosen here had previously been demonstrated to discriminate between normotensive and hypertensive individuals or exhibited changes associated with antihypertensive medication. Portions of the ADL questionnaire, particularly questions about drowsiness and sexual difficulties, were targeted to functional areas previously suspected to be associated with antihypertensive treatment in general or a specific medication. The Zung scale has been used extensively with geriatric populations and has been shown to be sensitive to subtle changes in affect in elderly patients.
Studies reporting negative results are often found to suffer from insufficient sample size and the attendant difficulty of having low power to detect true, underlying treatment differences. This study was designed to assure adequate power to test treatment differences among the four combination therapy regimens with regard to neuropsychological test changes from baseline to end of maintenance. The target sample size of 180 patients, 45 per treatment group, was sufficient to detect moderate across-treatment group differences of approximately 15% with 80% power. As 213 patients completed combination therapy, the actual power is higher. Furthermore, detection of true dosage regimen differences in the HCTZ monotherapy phase were virtually certain as 690 patients were randomly assigned in that phase.
In the present study, significant improvement was noted on many of the neuropsychological tests, but that may have come about because of practice effects related to repeated testing rather than blood pressure reduction or a specific drug effect. To evaluate that hypothesis, a substudy was conducted on a group of patients with entry criteria and baseline characteristics similar to those in the main study. Substudy patients were put on blinded placebo and given the test battery twice, 2-3 months apart. Improved performance at the second test was comparable in magnitude to that found in the diuretic titration phase. These results suggest that caution should be exercised in attributing improved test scores to clinical improvement and also indicate that the practice effect does not appear to mask actual deterioration.
Although few positive results were found, the consistency of improved ability to estimate time across all treatment groups further supports previous reports that hypertensive patients experience an impaired sense of time that improves with treatment. Furthermore, the construction of the baseline factors is consistent with previously known interrelations among the various components of the test battery. Thus, measurement error does not appear to be a problem in this study.
In summary, the drug combinations used did not appear to have major adverse effects on elderly, mildly to moderately hypertensive patients and generally were effective in controlling blood pressure. These findings are consistent with those reported by Fanner et al 16 with Framingham study patients. However, they are not entirely consistent with the results of Croog et al, 17 who reported that different drugs have differing impacts on quality of life; captopril was associated with improvement and methyldopa and propanolol with decrement. It is, of course, difficult to compare studies because of differences in severity of hypertension, age, racial composition, and dosage levels used, even for the same medications. Further studies might profitably investigate the basis for these discrepancies and the conditions under which antihypertensive drugs improve or impair function, as both effects have been reported.
In conclusion, this study suggests that neither blood pressure reduction per se nor the use of these specific medication regimens produce markedly adverse cognitive or behavioral consequences in elderly males with mild-to-moderate hypertension.
